Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H plus BC): A Brown University oncology group (BrUOG) study

被引：1
|
作者：
Lopresti, Mary Lorraine [1 ]
Bian, Jessica J. [1 ]
Sakr, Bachir J. [2 ]
Strenger, Rochelle S. [1 ]
Legare, Robert D. [2 ]
Fenton, Mary Anne [1 ]
Witherby, Sabrina M. [1 ]
Dizon, Don S. [1 ]
Pandya, Sonali V. [2 ]
Stuckey, Ashley R. [2 ]
Edmondson, David A. [2 ]
Gass, Jennifer S. [2 ]
Emmick, Christine M. [1 ]
Graves, Theresa A. [1 ]
Cutitar, Marlene [1 ]
Olszewski, Adam J. [1 ]
Sikov, William M. [2 ]
机构：
[1] Lifespan Canc Inst, Providence, RI USA
[2] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-16-19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-16-19
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)
    Fernandez Abad, Maria
    Calvo, Isabel
    Martinez, Noelia
    Herrero, Mercedes
    Quijano, Yolanda
    Duran, Hipolito
    Garcia Aranda, Mariola
    Suarez, Ana
    Lopez-Rios, Fernando
    Perez, Diego
    Perea, Sofia
    Hidalgo, Manuel
    Garca-Estevez, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749
  • [43] Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
    Kash, J.
    Barlow, W. E.
    Albain, K. S.
    Gralow, J. R.
    Lew, D.
    Flaherty, L. E.
    Royce, M. E.
    Hortobagyi, G. N.
    Livingston, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2-Positive Breast Cancer (BC).
    Gianni, L.
    Bianchini, G.
    Kiermaier, A.
    Bianchi, G.
    Im, Y-H
    Pienkowski, T.
    Roman, L.
    Liu, M-C
    Tseng, L-M
    Ratnayake, J.
    Szado, T.
    Ross, G. A.
    Valagussa, P.
    CANCER RESEARCH, 2011, 71
  • [45] Effect of a combination of pertuzumab, trastuzumab, and weekly paclitaxel on pCR rates and side-effect profile as a neoadjuvant treatment regimen for HER2-positive breast cancer.
    Gupta, Niraj K.
    Giblin, Erica
    Leagre, Christopher A.
    Govert, Kristen
    Givens, Stanley
    Chichester, Tiffany
    Locker, Matthew
    Bhayani, Parin
    Burnett, Riesa
    Spivey, Tara
    Cohen, Stephanie
    Paul, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study
    Liu, Yin
    Zuo, Wen-Jia
    Wang, Ruo-Xi
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    CANCER RESEARCH, 2023, 83 (05)
  • [47] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [48] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    World Journal of Surgical Oncology, 21
  • [49] Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
    Ewer, Michael
    Baselga, Jose
    Clark, Emma
    Benyunes, Mark
    Ross, Graham
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Neoadjuvant carboplatin and weekly paclitaxel for stage Ib-IIIa non-small cell lung cancer (NSCLC): A Brown University Oncology Group (BrUOG) phase II study
    Ng, T.
    Berz, D.
    Birnbaum, A.
    Dipetrillo, T. A.
    Henderson, D.
    Kennedy, T.
    Ready, N. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345